Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC)

Patil, Suyash M.; Sawant, Shruti S.; Kunda, Nitesh K.

doi:10.1016/j.ijpharm.2021.121046

Cited by 49 publications

(23 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the successful internalization of the BQLC in lung cancer cells (A549 cells) has been revealed, which resulted in the decrease of the half-maximal inhibitory concentration (IC50) (3-fold), as well as in the significant inhibition of tumor growth compared to free bedaquiline. The excellent aerosolization performance and improved anti-cancer activity demonstrated by the obtained results highlight the potential of BQLC as NSCLC therapy [97].…”

Section: Cancer Therapymentioning

confidence: 74%

“…Patil et al developed an inhalable bedaquiline-loaded cubosome nanocarriers for non-small cell lung cancer treatment. The ζ-potential measurements showed that the nanocarriers were cationic and stable regarding particle size for periods of eight weeks at storage conditions [97].…”

Section: Indirect Techniques Dynamic Light Scattering (Dls) and Zeta(...mentioning

confidence: 94%

“…Additionally, it is worth noticing the development of inhalable bedaquiline-loaded cubosomes (BQLC) for non-small cell lung cancer treatment (NSCLC) (Figure 9) [97]. These nanoparticles were prepared via a solvent evaporation technique, showing excellent characteristics such as particle size (150 nm), zeta potential (35 mV), and aerosolization behavior.…”

Section: Cancer Therapymentioning

confidence: 99%

See 2 more Smart Citations

A Versatile Nanocarrier—Cubosomes, Characterization, and Applications

et al. 2022

View full text Add to dashboard Cite

The impact of nanotechnology on the exponential growth of several research areas, particularly nanomedicine, is undeniable. The ability to deliver active molecules to the desired site could significantly improve the efficiency of medical treatments. One of the nanocarriers developed which has drawn researchers’ attention are cubosomes, which are nanosized dispersions of lipid bicontinuous cubic phases in water, consisting of a lipidic interior and aqueous domains folded in a cubic lattice. They stand out due to their ability to incorporate hydrophobic, hydrophilic, and amphiphilic compounds, their tortuous internal configuration that provides a sustained release, and the capacity to protect and safely deliver molecules. Several approaches can be taken to prepare this structure, as well as different lipids like monoolein or phytantriol. This review paper describes the different methods to prepare nanocarriers. As it is known, the physicochemical properties of nanocarriers are very important, as they influence their pharmacokinetics and their ability to incorporate and deliver active molecules. Therefore, an extensive characterization is essential to obtain the desired effect. As a result, we have extensively described the most common techniques to characterize cubosomes, particularly nanocarriers. The exceptional properties of the cubosomes make them suitable to be used in several applications in the biomedical field, from cancer therapeutics to imaging, which will be described. Taking in consideration the outstanding properties of cubosomes, their application in several research fields is envisaged.

show abstract

Section: Cancer Therapymentioning

confidence: 74%

Section: Indirect Techniques Dynamic Light Scattering (Dls) and Zeta(...mentioning

confidence: 94%

Section: Cancer Therapymentioning

confidence: 99%

See 1 more Smart Citation

A Versatile Nanocarrier—Cubosomes, Characterization, and Applications

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[98] The findings revealed that the cubosome formulation containing the medication exhibited considerable cytotoxicity in A549 cells, in addition to inducing apoptotic cell death, and had anti-invasive properties. [103] 12…”

Section: Anticancer Activity Of Cubosomementioning

confidence: 99%

“…The cytotoxicity analysis revealed that the bedaquiline-loaded cubosomes exhibited considerable cytotoxicity in A549 cells through apoptosis. It is the first research to use cubosomes in inhalation treatment, and it is the most promising [ 103 ].…”

Section: Anticancer Activity Of Cubosomementioning

confidence: 99%

Development, Therapeutic Evaluation and Theranostic Applications of Cubosomes on Cancers: An Updated Review

Almoshari

2022

Pharmaceutics

View full text Add to dashboard Cite

Cancer is a group of disorders characterized by aberrant gene function and alterations in gene expression patterns. In 2020, it was anticipated that 19 million new cancer cases would be diagnosed globally, with around 10 million cancer deaths. Late diagnosis and interventions are the leading causes of cancer-related mortality. In addition, the absence of comprehensive cancer therapy adds to the burden. Many lyotropic non-lamellar liquid-crystalline-nanoparticle-mediated formulations have been developed in the last few decades, with promising results in drug delivery, therapeutics, and diagnostics. Cubosomes are nano-structured liquid-crystalline particles made of specific amphiphilic lipids in particular proportions. Their ability to encapsulate lipophilic, hydrophilic, and amphiphilic molecules within their structure makes them one of a kind. They are biocompatible, versatile drug carriers that can deliver medications through various routes of administration. Many preclinical studies on the use of cubosomes in cancer treatment and theranostic applications have been conducted. However, before cubosomes may be employed in clinical practice, significant technical advances must be accomplished. This review summarizes the development of cubosomes and their multifunctional role in cancer treatment based on the most recent reports.

show abstract

Smart Lipid‐Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions

Shahrivar,

Fakhr,

Abbasgholinejad

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer‐related deaths worldwide, and conventional treatments for the disease often fall short. Smart nanoparticles (NPs) are emerging as a promising strategy for the treatment of lung cancer, owing to their ability to selectively deliver therapeutic agents to cancer cells while minimizing off‐target effects. Smart NPs can respond to specific stimuli such as changes in pH, temperature, or enzymes, allowing them to release their cargo only when triggered. Among the various types of smart NPs, lipid‐based NPs, including liposomes, solid lipid nanoparticles, cubosomes, and extracellular vesicles, have garnered the highest interest due to their biocompatibility, low toxicity, and versatility in encapsulating a wide variety of drugs and genetic material. This review discusses the current status of smart lipid‐based NPs in lung cancer treatment, including recent advances in targeting strategies, stimuli‐responsive NPs, and combination therapies. The challenges and opportunities associated with translating smart lipid‐based NPs for lung cancer treatment into clinical applications are also discussed. This review highlights the potential of smart lipid‐based NPs to revolutionize lung cancer treatment and improve patient outcomes.

show abstract

Inhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC)

Cited by 49 publications

References 47 publications

A Versatile Nanocarrier—Cubosomes, Characterization, and Applications

A Versatile Nanocarrier—Cubosomes, Characterization, and Applications

Development, Therapeutic Evaluation and Theranostic Applications of Cubosomes on Cancers: An Updated Review

Smart Lipid‐Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions

Contact Info

Product

Resources

About